We would like to thank all of our speakers and chairs for their invaluable contributions at the 2022 E-Cigarette Summit which was held in Washington on May 17th.  We are currently working on the 2023 Summit and will announce our new speakers next year.

The 2022 Opening Keynote and Summit chair was delivered by David L. Ashley RADM (retired) US Public Health Service – Research Professor, Department of Population Health Sciences , School of Public Health, Georgia State University

The Closing Keynote was given by Dr Vaughan Rees – Director of the Center for Global Tobacco Control, Harvard T.H. Chan School of Public Health


Prof David L. Ashley Ph.D

RADM (retired) US Public Health Service: Research Professor

School of Public Health - Georgia State University

David Ashley is currently a Research Professor in the School of Public Health at Georgia State University. He received his PhD in Physical Chemistry in 1982 from Emory University. He spent 27 years, from 1983-2010 at the Centers for Disease Control and Prevention, National Center for Environmental Health. During this time, he carried out research on the impact of toxic chemicals in the environment on health, developed methods and systems to respond to chemical and biological terrorism, and built a tobacco product and biomarker laboratory. He has performed extensive research related to the impact of cigarette design and contents on the emissions from tobacco products, how people use tobacco products, and resulting biomarkers of exposure. From 2010 until 2017, he was the inaugural Director of the Office of Science at the Center for Tobacco Products (CTP) of the U.S. Food and Drug Administration. In that role, he was instrumental in carrying out the regulatory authorities of the 2009 law which gave FDA authority to regulate tobacco products. He has published over 180 peer-reviewed articles and book chapters related to biophysics, environmental chemicals, biomarkers of exposure and the constituents of tobacco and tobacco smoke. He retired in May 2016 at the Public Health Service rank of Assistant Surgeon General. He has presented extensively at scientific meetings on the chemistry of tobacco and tobacco smoke and biomarkers of exposure. He serves on the World Health Organization (WHO) Study Group for Tobacco Product Regulation and was the Chair of the WHO Tobacco Laboratory Network from 2006 until 2010.

Prof Thomas J. Glynn, PhD

Adjunct Lecturer

Stanford Prevention Research Centre, Stanford University School of Medicine

Dr. Glynn is, from 2014 to the present, Adjunct Lecturer, Stanford Prevention Research Center, Stanford University School of Medicine and Executive Team Member, Mayo Clinic Global Bridges Initiative. From 1998 to 2014, he was Director, Cancer Science and Trends and Director, International Cancer Control at the American Cancer Society (ACS).   Prior to the ACS, Dr. Glynn was, from 1991 to 1994, Associate Director of the U.S. National Cancer Institute's (NCI) Cancer Control Science Program and, from 1991 to 1998, Chief of the NCI's Cancer Control Extramural Research Branch.. From 1983 to 1991, he was Research Director for the NCI's Smoking, Tobacco, and Cancer Program and from 1978 to 1983, he was a Research Psychologist at the National Institute on Drug Abuse.   Dr. Glynn has published widely on cancer and tobacco use prevention and control, both in the scientific literature and for consumer, professional, and patient education. In addition to his work at the ACS and NCI, he has served as a consultant on cancer control and tobacco issues to such groups as the National Academy of Sciences/Institute of Medicine, the National Research Council, the Robert Wood Johnson Foundation, the WHO, a variety of pharmaceutical organizations, and national, state and local governments.   He has also served as a Senior Scientific Reviewer for the U.S. Surgeon General's Reports on Tobacco and Health, as Director of the World Health Organization Study of Health, Economic, and Policy Implications of Tobacco Growth and Consumption in Developing Countries, and has been active in tobacco control programs in Eastern Europe, Central America, and India. He is a Fellow of the Society for Research on Nicotine and Tobacco and his awards include the U.S. National Institutes of Health Merit Award, the Polish Ministry of Health Service Award, the Guatemala National Council for Tobacco Prevention and Control Meritorious Service Award, the Society for Research on Nicotine and Tobacco John Slade Award, and the American Society of Preventive Oncology Joseph W. Cullen Memorial Award.  

Prof Robin Mermelstein

Distinguished Professor of Psychology and IHRP Director

University of Illinois, Chicago

Robin Mermelstein, PhD. is Distinguished Professor, Psychology Department; Director of the Institute for Health Research and Policy at the University of Illinois at Chicago (UIC), and Co-Director of UIC’s Center for Clinical and Translational Science.  Dr. Mermelstein has been active in health-behavior research for 30 years, with continuous NIH funding as a Principal Investigator on grants since 1986. Dr. Mermelstein was acknowledged by the NCI as a Research Pioneer in the Division of Cancer Control and Population Sciences. She is nationally recognized for her expertise in understanding trajectories and developmental patterns of youth tobacco use, for employing novel approaches to studying contextual factors in the development of nicotine dependence and health risk behaviors, for developing innovative health behavior clinical interventions for adolescents and adults, and for methodological issues in conducting tobacco-related research. She has been the PI of several large-scale, multidisciplinary program project and center grants, as well as the Director of a national program or the Robert Wood Johnson Foundation. Dr. Mermelstein has served on many NIH advisory and review committees, including being a former standing member of the NCI-A Cancer Centers review committee; a former member of the External Scientific Advisory Panel for the NCI’s Science of Research and Technology Branch; co-Chair of the NCI’s Tobacco Control Priorities Consultant Group; a former standing member of the National Institute on Drug Abuse’s K-award study section; and a current member of the External Scientific Advisory Board for the Adolescent Brain and Cognitive Development Study (ABCD Study) of NIH. She has been acknowledged for her scientific accomplishments by several national and international research societies, including being named a Fellow of the Association of Psychological Science, a Fellow of the Society of Behavioral Medicine, and a Fellow of the Society for Research in Nicotine and Tobacco. She is a past President of the Society for Research on Nicotine and Tobacco (2015-2016).  

Cliff Douglas, JD

Director, Tobacco Research Network, Adjunct Professor, Department of Health Management and Policy

School of Public Health, University of Michigan

Cliff Douglas is the Director of the University of Michigan Tobacco Research Network, an adjunct professor at the School of Public Health, and a co-principal investigator for the Center for the Assessment of Tobacco Regulations at the University of Michigan. He was the American Cancer Society’s Vice President for Tobacco Control from 2015 to 2020, where he led the development of a comprehensive new public health approach to tobacco control, set forth in the American Cancer Society Public Health Statement on Ending Combustible Tobacco Use in the United States (2018), and co-founded the National Partnership on Behavioral Health and Tobacco Use, which is dedicated to increasing cessation and reducing mortality and illness in smokers with mental health conditions. He also provided expertise on issues related to the changing tobacco product marketplace and guided ACS’s efforts to educate the public about the impact of smoking on COVID-19. Previously, he served as a policy advisor for the Assistant Secretary for Health and the U.S. Surgeon General in the Obama administration, where he was a lead author of the Tobacco Control Strategic Action Plan for the U.S. Department of Health and Human Services. Earlier in his career, he coordinated the successful national campaign to make all commercial airline flights smoke-free and participated as an attorney and public health expert in the litigation that resulted in adoption of the Master Settlement Agreement. As special counsel for Congressman Martin Meehan and the Congressional Task Force on Tobacco and Health in the U.S. House of Representatives, he wrote legislation and prepared the 111-page prosecution memorandum that persuaded the U.S. Attorney General to launch a criminal investigation into the tobacco industry and later file the Justice Department’s landmark racketeering (RICO) action against the major tobacco companies. As told in Civil Warriors: The Legal Siege on the Tobacco Industry, Mr. Douglas also helped tobacco industry whistleblowers go public, and initiated an ABC News expose on the tobacco companies’ engineering of their products to cause dependency that led the Food and Drug Administration to open a two-year investigation and regulate tobacco for health and safety for the first time.

Dr Vaughan W. Rees

Director of the Center for Global Tobacco Control

Harvard T.H. Chan School of Public Health

Dr. Rees is Director of the Center for Global Tobacco Control, and Senior Lecturer on Social and Behavioral Sciences at Harvard T.H. Chan School of Public Health in Boston, USA. His research focuses on tobacco control, which entails strategies to address a public health epidemic projected to cause the deaths of one billion people in the 21st century, mostly from within developing countries.  Tobacco products are highly addictive, yet legal, and, in most parts of the world, abundantly available. As a public health field, tobacco control aims to reduce tobacco harms through evidence-informed policy and other interventions. Among the six classic “pillars” of tobacco control, five are represented in his published research, including tobacco cessation treatment strategies, strategies to reduce secondhand smoke exposure, regulation of product design and abuse liability, regulation of tobacco product marketing and messaging, and tobacco taxes. The multifaceted nature of tobacco control requires multidisciplinary approaches to research. Dr. Rees uses a diverse set of methodological approaches to generate evidence needed to develop effective public health solutions, including programs and policies aimed at reducing the health burden of tobacco use. He directs the Tobacco Research Laboratory at the Harvard Chan School, where he conducts research to understand how tobacco manufacturers design their products to influence human use and dependence. This work has contributed directly to regulatory strategies in the U.S. and internationally. Other research by Dr. Rees focuses on reducing the burden of tobacco-related harm among underserved communities, with a focus on interventions to eliminate secondhand smoke exposure among children from low income and racially/ethnically diverse backgrounds. Dr. Rees’ academic background is in health psychology (substance use and dependence), and he trained at the National Drug and Alcohol Research Centre at the University of New South Wales in Sydney, Australia, and did postdoctoral training through the National Institute on Drug Abuse in the United States.

Prof Neal L. Benowitz MD

Professor of Medicine Emeritus (Active)

University of California, San Franciso

Neal L. Benowitz, MD, is Emeritus Professor of Medicine and Bioengineering & Therapeutic Sciences, and Chief of the Division of Clinical Pharmacology and Experimental Therapeutics, University of California, San Francisco (UCSF). He received his medical degree from the University of Rochester School of Medicine in 1969, following which he served as a resident in internal medicine at the Bronx Municipal Hospital Center from 1969 to 1971. He then completed a postdoctoral fellowship in clinical pharmacology at UCSF and joined the faculty in 1974. His research interests have focused primarily on the human pharmacology and toxicology of nicotine. He has published more than 700 research papers. Dr Benowitz also maintains an active clinical practice in cardiovascular medicine and medical toxicology.  Dr Benowitz was a scientific editor of the 1988 United States Surgeon General’s Report on Smoking and Health: Nicotine Addiction; a scientific editor of the 2001 NCI Monograph 13 Report on Risks Associated with Smoking Cigarettes with Low Machine-Measured Yields of Tar and Nicotine; and served as section editor for the 2010 Surgeon General’s Report on How Tobacco Smoke Causes Disease. He,has served as a member of the National Institutes of Health Pharmacology Study Section, the FDA Nonprescription Drug Advisory Committee and the FDA Tobacco Products Science Advisory Committee. He is a member of a number of medical societies, including the American Society for Clinical Investigation and the Association of American Physicians. He has served as President of the American Society for Clinical Pharmacology and Therapeutics and as President of the Society for Research on Nicotine and Tobacco. Dr Benowitz has received the Ove Ferno, Alton Ochsner, and Rawls-Palmer Progress in Medicine awards, and the Oscar B. Hunter Memorial Award in Therapeutics for his research on nicotine, tobacco, and health, and was the 2002 UCSF Annual Distinguished Clinical Research Lecturer.

Andy Hyland

Scientific Principal Investigator, NIH/FDA PATH Study

Roswell Park Comprehensive Cancer Center

Andrew Hyland is the Chair of the Department of Health Behavior at Roswell Park Comprehensive Cancer Center and the Scientific Principal Investigator of the Population Assessment of Tobacco and Health (PATH) study, which is supported by the National Institute on Drug Abuse and the Food and Drug Administration to study more than 46,000 adults and children nationally over a 14 year period to understand changes in tobacco use behaviors and health. Dr. Hyland’s research program is focused on providing an evidence base to inform policies, regulations, and interventions to reduce the disease burden caused by tobacco by as much and to as many people as quickly as possible.  He has conducted numerous funded clinical and population-based studies, published more than 270 papers, and has been recognized for his service and scholarship by both local and international agencies.

Prof Peter Hajek

Professor of Clinical Psychology & Director of the Tobacco Dependence Research Unit

Wolfson Institute of Public Health, Queen Mary University of London

Peter Hajek is Professor of Clinical Psychology and Director of the Tobacco Dependence Research Unit at the Wolfson Institute of Preventive Medicine, Queen Mary University of London. His research is concerned primarily with understanding health behaviours, and developing and evaluating both behavioural and pharmacological treatments for dependent smokers and for people with weight problems. Professor Hajek is a member of a number of expert groups, advisory bodies and editorial boards, and has authored or co-authored over 350 publicatio

Dr Jamie Hartmann-Boyce

Associate Professor and Editor, Cochrane Tobacco Addiction Group

Nuffield Department of Primary Care Health Sciences, University of Oxford

Jamie Hartmann-Boyce is Associate Professor and departmental lecturer with the Centre for Evidence-Based Medicine at the Nuffield Department of Primary Care Health Sciences, University of Oxford. Her particular interests lie in evidence synthesis (both quantitative and qualitative) and the communication of complex information and data to inform policy and public action. Her research mainly consists of complex evidence synthesis work. She leads the Cochrane review of electronic cigarettes for smoking cessation, which is now a living review funded by Cancer Research UK, updated monthly, and is an editor for the Cochrane Tobacco Addiction Group.

Prof Scott Sherman

Professor of Population Health, Medicine and Psychiatry

NYU Grossman School of Medicine

Dr. Sherman is currently a Professor of Population Health, Medicine and Psychiatry NYU Grossman School of Medicine. He received his MD from NYU School of Medicine and completed an MPH in Epidemiology/Biostatistics at Boston University School of Public Health. He is a practicing physician in internal medicine and geriatrics and sees patients at the Veterans Health Administration (VA) in New York. His research studies have focused on how to redesign health care systems to better help people quit smoking. He is particularly focused on population health studies, examining the effectiveness of interventions in routine practice, as well as how to disseminate and implement them. He is currently studying the use of text messaging to support smoking cessation and behavioral economic strategies to help increase the use of tobacco cessation treatment. In addition, he is studying the impact of e-cigarettes for harm reduction in smokers with comorbid condition, such as chronic obstructive pulmonary disease or coronary artery disease. He has over 200 peer-reviewed publications in scientific journals and is currently leading 8 large grants, with funding from the National Institutes of Health, the VA and foundations.

Kathleen Crosby

Director, Office of Health Communication & Education

FDA Center for Tobacco Products

Kathleen Crosby is currently Director of the Office of Health Communication and Education at the FDA Center for Tobacco Products (CTP). The office is responsible for conducting public education, stakeholder outreach, and regulatory communication programs designed to ensure FDA's success in implementing the Tobacco Control Act. These efforts include developing breakthrough communication strategies to reduce youth tobacco use, helping current tobacco users quit, and building stakeholder understanding of and compliance with FDA tobacco product regulations. Since joining CTP in February 2011, Ms. Crosby has led the development and implementation of multiple public education campaigns targeting at-risk and underserved populations, including FDA's first-ever national youth tobacco prevention campaign, "The Real Cost." From its launch in Feb. 2014 to Nov. 2016, the award-winning campaign has prevented up to 587,000 youth ages 11 to 19 from initiating smoking, half of whom might have gone on to become established adult smokers. Ms. Crosby's career spans 20 years of senior-level marketing and advertising experience working on large-scale multimedia campaigns and education programs for major national brands in both the private and non-profit sectors. Before beginning at CTP, Ms. Crosby was Senior Vice President, Group Campaign Director of the Washington office of the Ad Council, where she successfully managed day-to-day operations. In her nine years at the Ad Council, she created integrated communication programs that have proven to inspire attitudinal and behavioral change for America's most pressing social issues. One of Ms. Crosby's leadership roles at the Ad Council was as Campaign Director for 17 United States government agencies, including the Departments of Health and Human Services, Transportation, Homeland Security, Energy, Defense, Agriculture, and Justice. Previously, while serving as Vice President of Strategic Planning at Arnold Worldwide, Ms. Crosby oversaw the strategic development of the Legacy Foundation's "Truth" campaign, which is widely regarded as one of the most potent and successful tobacco prevention campaigns ever conducted in the United States. Ms. Crosby received a B.A. degree from University of Colorado in Political Science with a minor in Spanish.

Associate Prof Jennifer Pearson

Associate Professor in Health Administration and Policy

School of Public Health, University of Nevada, Reno

Jennifer Pearson is an Associate Professor in Health Administration and Policy in the School of Public Health at the University of Nevada, Reno.  Broadly, her research focuses on how regulation of tobacco and cannabis product characteristics, packaging, and advertising affects consumer behavior and public health outcomes. Dr. Pearson has authored over 100 scientific peer-reviewed scientific articles on tobacco and cannabis policy and published in high-impact journals such as the New England Journal of Medicine, the American Journal of Public Health, and Tobacco Control, and is a Deputy Editor of Nicotine & Tobacco Research. Dr. Pearson earned her doctorate in Public Health from the Johns Hopkins Bloomberg School of Public Health in 2011, and her Master of Public Health degree from George Washington University in 2007. Dr. Pearson started her career in public health as a Tobacco Education Coordinator for the American Lung Association of Nevada and served as a US Peace Corps volunteer in Guinea from 2002-2004.  

Jeff Lynch

Facilitator Prevention/Intervention Education, CHOICES Prevention Programs

Tulare County Office of Education

Jeff Lynch works as a facilitator in the Prevention Intervention Education, Choices Program for Tulare County Office of Education.  He received his Bachelor of Arts degree from Brandman University graduating Summa cum laude.  The mission of the Tulare County Office of Education is to provide quality service and support to all students and school districts throughout Tulare County. This is achieved by promoting life-long learning opportunities that will help individuals lead healthy and productive lives. The program is dedicated to working collaboratively with students, parents, school districts, public agencies, and communities to prepare students to meet the challenges of the 21st century. Through the Tobacco Use Prevention Education (TUPE) Tier Two grant, Jeff facilitates 13 staff in supporting 40,000 students from both rural and urban school sites in Tulare County. The curriculum implemented ensures all students are educated on the dangers of various tobacco products.

Prof Kevin M. Gray, M.D

Professor of Psychiatry and Behavioral Sciences

Medical University of South Carolina

Kevin M. Gray, M.D., is a Professor in the Department of Psychiatry and Behavioral Sciences and serves as Assistant Provost for Research Advancement at the Medical University of South Carolina (MUSC). As a child and adolescent psychiatrist and physician-scientist co-leading the MUSC Youth Collaborative, he conducts National Institutes of Health supported clinical research, contributing novel advances to treatments for substance use disorders in adolescents and young adults. Dr. Gray serves on the Board of Directors for the American Academy of Addiction Psychiatry, is Associate Editor of the Journal of Child and Adolescent Psychopharmacology, and is Principal Investigator of the American Academy of Child and Adolescent Psychiatry Physician Scientist Program in Substance Use. In addition to clinical, administrative, and research efforts, Dr. Gray is dedicated to education, providing didactic instruction across training programs and mentoring multiple early career faculty and trainees in clinical research.

Dr Ray Niaura

Professor of Social & Behavioural Health & Co-Director of the Tobacco Research Lab

School of Global Public Health, New York University

Dr. Niaura is a Professor of Social and Behavioral Health at NYU GPH and the Co-Director of the Tobacco Research Lab. His research interests are two-fold: studying the bio-behavioral substrates of tobacco dependence, including factors that influence adolescent and early adult tobacco use trajectories; and evaluating behavioral and pharmacological treatments for cessation, specifically with regard to addressing public health disparities in tobacco related burdens of illness and disability. He comes to NYU from the Washington, DC-based Schroeder Institute (SI) for Tobacco Research and Policy Studies where he was Director of Science and Training for eight years. Dr. Niaura has extensive expertise in tobacco dependence and treatment, having published over 400 peer-reviewed articles, commentaries and book chapters in this field. He has been PI or co-I of over 70 NIH-funded grants and is the former President of the Society of Nicotine and Tobacco Research.

Matthew R. Holman

Director, Office of Science (OS),Center for Tobacco Products (CTP)

U.S. Food and Drug Administration

Matthew R. Holman, Ph.D. is currently Director of the Office of Science at the Center for Tobacco Products (CTP) of the U.S. Food and Drug Administration (FDA). He was appointed to that position in January 2017. The Office of Science at CTP is responsible for identifying, developing, and enhancing the science related to tobacco products, their use, and the resulting morbidity and mortality so that regulatory decisions will have the greatest impact on improving public health. To accomplish this goal, they provide the scientific support for regulations and guidance, review tobacco product applications, evaluate the knowledge basis for regulatory decisions, and carry out research to fill the gaps in scientific knowledge related to tobacco product regulation. He received his Ph.D. in Biochemistry from the University of Maryland at College Park in 2000. Before taking on his current position, Dr. Holman served as Director of the Division of Product Science within CTP’s Office of Science for six years. In this position, he oversaw evaluation of the composition and design of tobacco products. In addition, he was involved in chemical, microbiological, and engineering research on tobacco products, resulting in numerous publications in peer-reviewed scientific journals. During this time, Dr. Holman also served as Technical Project Lead (TPL) in reviewing over a thousand SE Reports. As TPL, he was responsible for the overall scientific review of SE Reports by CTP. Before his tenure at CTP, he worked in FDA’s Center for Drug Evaluation and Research (CDER) on over-the-counter drug products. He served in a few positions within CDER, with his last position being Deputy Director of the Division of Nonprescription Regulation Development. In this role, he was involved in the publication of approximately 50 rulemakings, guidance documents, and other Federal Register notices.

David Graham

Chief Impact Officer


David Graham is Chief Impact Officer at NJOY, a role which leads efforts across the company to maximize the positive impact on public health of the company’s products and services through increasing their reach and effectiveness while including oversight of regulatory affairs for the company. He has extensive experience in nicotine and non-nicotine new product development, tobacco control policy, and related regulation in the international healthcare and e-vapor industries spanning ~ 25 years. Beginning with nicotine replacement therapy (NRT)/smoking cessation products in the UK in 1992, followed by International product and category development roles in Sweden, he moved to the USA in 2000 with Pharmacia, subsequently becoming part of Pfizer and then moving to Johnson & Johnson.  In 2013, he joined NJOY to lead the regulatory affairs, quality & compliance function for the company and prepare for regulation by FDA and other regulatory agencies in the US and abroad. In addition to multiple interactions with FDA, and other regulatory agencies internationally, David co-led NJOY’s engagement with the National Institute of Drug Abuse (NIDA) on its Small Business Innovation Research (SBIR) award for NJOY to develop an Electronic Nicotine Delivery System (ENDS) for use for clinical research in smoking cessation, leading to the establishment of the first FDA Drug Master File (DMF) for ENDS products. In late 2016, David co-founded and was President of Reveritas Group, a multi-partner consultancy firm of specialists and preferred providers formed to aid ENDS companies navigate all aspects of FDA’s Premarket Tobacco Application (PMTA) process via a total programming approach, and/or provide select outsourced resources as required. Following FDA’s extension of the PMTA compliance deadline, David returned to NJOY in August 2017 in his current role.  David is a graduate of Columbia University with a Master’s in Public Policy & Administration.

Clive Bates


Counterfactual Consulting Ltd

Clive Bates has had a diverse career in the public, private and not-for-profit sectors.  He started out with the IT company, IBM, then switched career to work in the environment movement. From 1997-2003 he was Director of Action on Smoking and Health (UK), campaigning to reduce the harms caused by tobacco. In 2003 he joined Prime Minister Blair’s Strategy Unit as a civil servant and worked in senior roles in the public sector and for the United Nations in Sudan. He is now Director of Counterfactual, a consulting and advocacy practice focussed on a pragmatic approach to sustainability and public health.

Marc Slis

Vape Shop Owner - Vaper & Former Smoker

Onboard Seismic QC

High school dropout and runaway at 14 years old.  After 20 years working in the building trades, I obtained a bachelor’s degree in Geology, then spent 18 years at sea, working as a marine seismic geophysicist, 5 years as a geophysical consultant managing seismic surveys around the globe for the petroleum industry and 3 years conducting monitoring and Clean Water Act enforcement of multiple public water supplies, as well as surface and ground water sources, for a Native American Indian tribe. Vape shop owner of a single store in a rather small and remote, rural community in the Midwestern state of Michigan for the last 6 ½ years, purchased after quitting a 41-year smoking habit there 8 years ago. One of the founding members of Michigan Vape Shop Owners (MVSO), lobbying for common-sense vaping regulation and legislation at the state level and also had the dubious honor of suing my Governor, state and state health department on behalf of Michigan vapor businesses, successfully stopping an industry-killing flavor ban in 2019 and 2020. For the last 1 ½ years, I’ve employed a 5 yr old, female pit bull terrier named Bernie at my shop, both enhancing and encouraging successful smoking cessation. She’s well-known in both the vaping community and industry and is featured in an online smoking cessation program developed by Dr. Marewa Glover, director of the independent Centre of Research Excellence: Indigenous Sovereignty & Smoking based in Auckland, New Zealand.

Prof Kathleen. S Hoke, J.D.

Director of the Legal Resource Center for Public Health Policy

University of Maryland Carey School of Law

Kathleen is a Law School Professor, Director of the Legal Resource Center for Public Health Policy, and Director of the Network for Public Health Law-Eastern Region, at the University of Maryland Carey School of Law. Through the Center and Network, Kathleen provides technical legal assistance to state and local health officials, legislators, researchers, and organizations working to use law and policy change to improve public health. With the Legal Resource Center, Kathleen supports Maryland policymakers, legislators, public health officials, and community organizations work through myriad legal issues related to tobacco control and prevention, regulation of gambling, and injury prevention. As Director of the Network’s Eastern Region, Kathleen studies different approaches to improving public health through housing law and policy, working with state and local public health officials and housing advocates on law and policy change to create affordable, healthy housing. Kathleen’s work with the Network also focuses on regulation of cannabis, scope of practice of health professionals, dyamics of the opioid epidemic, immigrants and public health, and more. As a Professor at Maryland Carey Law for nearly two decades, Kathleen directs the Public Health Law Clinic and teaches Public Health and the Law and Legal Analysis and Writing. Kathleen’s interdisciplinary work has resulted in co-authored publications across the spectrum, including in the Journal of Law, Medicine and Ethics; Injury Prevention; Journal of Urban Health; Journal of Health Care Law and Policy; and the Journal of Health Care for the Poor and Underserved. Kathleen was given the UMB President’s Award for Excellence in 2020 and in 2016 received the Jennifer Robbins Award for the Practice of Public Health Law by the American Public Health Association Law Section. In 2020, Kathleen accepted a position on the editorial board of the CDC’s publication, Preventing Chronic Disease. She serves a variety of professional organizations and has been appointed by Maryland’s Governor to the Maryland State Council on Cancer Control. Kathleen graduated as a member of the Order of the Coif from the University of Maryland School of Law in 1992, completed a clerkship with the Honorable Lawrence Rodowsky of the Maryland Court of Appeals and served with distinction as an Assistant Attorney General and Special Assistant to the Attorney General of Maryland prior to joining the School of Law in 2002.

Prof David Levy

Professor of Oncology

Lombardl Comprehensive Cancer Center, Georgetown University

David Levy has a PhD in Economics from UCLA and is currently a Professor of Oncology at Georgetown. He has published over 200 papers, including articles in the American Economic Review, American Journal of Public Health, JAMA, Lancet, Medical Care, American Journal of Preventive Medicine, Obesity Review, Tobacco Control, and the Review of Economics and Statistics. His work spans topics in public health and industry behavior.  Dr. Levy has been principal investigator of grants from the Centers for Disease Control and Prevention, the World Health Organization, the National Cancer Institute, the National Institute on Drug Abuse, Bloomberg/Gates Foundation, European Union, and the Robert Wood Johnson Foundation.  He is currently the principal investigator of an FDA TCORS, and grants from the National Cancer Institute to the ITC project and to the CISNET Lung group.  Dr. Levy oversees the design and development of the SimSmoke tobacco policy simulation model, which predicts the effect of tobacco policies, such as tax increases, smoke-free air laws, media campaigns, youth access policies, and cessation treatment policies, on smoking rates and tobacco-related deaths. He has developed models for 10 states and for over 60 countries. He is currently developing simulation models that incorporate the use of smokeless tobacco and e-cigarettes.

Prof Dorothy K. Hatsukami

Professor, Department of Psychiatry and Behavioral Sciences

University of Minnesota

Dorothy K. Hatsukami, Ph.D. is the Professor of Psychiatry and Behavioral Sciences, Forster Family Chair in Cancer Prevention and Associate Director of Cancer Prevention and Control of the Masonic Cancer Center at the University of Minnesota.   Her areas of expertise include nicotine addiction and its treatment and tobacco regulatory science assessing the toxicity, appeal and addictiveness of various tobacco products.  She has over 450 peer reviewed publications and has received a number of awards for her work.  She has served on numerous scientific advisory boards or councils for the U.S. government including the FDA Tobacco Product Scientific Advisory Committee s.  She is currently a member of the World Health Organization Study Group on Tobacco Product Regulation.  She served as president of two scientific organizations, the College on Problems of Drug Dependence and the Society for Research on Nicotine and Tobacco.

Ben Youdan


Youdan Consulting - New Zealand

Ben Youdan has campaigned professionally for nearly 20 years, and has over a decade of experience leading charitable organisations in the UK and New Zealand. His career has taken us from running the biggest health awareness day in the UK, to setting up a major community initiative in south Auckland. He's run government funded social marketing programmes the UK and New Zealand, headed political campaign teams and been a regular media commentator.  He moved to New Zealand in 2006 to run ASH, where he campaigned for the Smokefree 2025 goal. He left ASH in 2013 to lead the election campaign for the Green Party where he overhauled the campaign systems, delivering the biggest ever ground campaign in the Party’s history.  

Professor Ann McNeill

Professor of Tobacco Addiction

Institute of Psychiatry, Psychology & Neuroscience,, Kings College London

Ann McNeill is a Professor of Addictions in the National Addiction Centre with a focus on tobacco. She graduated from the University of Nottingham with a first class joint honours degree in zoology and psychology and then carried out her PhD at the Institute of Psychiatry focusing on the development of dependence on smoking. Since that time she has held a variety of academic and public sector posts focusing largely on tobacco control research. Ann has an established international reputation, receiving a World Health Organisation award for contributions to tobacco control in 1998. She has published more than 250 academic papers book chapters, reports and opinion pieces on the subject and her research ranges across prevention, cessation, harm reduction and local, national and international policy. Ann was a co-author of the recent systematic review of tobacco product packaging which underpinned the recent government consultation on plain packaging and has a particular interest in the relationship between smoking, mental health and inequalities. She is Deputy Director of the UK Centre for Tobacco Control Studies. Competing Interest: None Stated

Dr. Nancy A. Rigotti, MD

Professor of Medicine, Harvard Medical School

Director, Tobacco Research & Treatment Center, Massachusetts General Hospital, Boston

Nancy Rigotti, MD, is an internationally known expert in tobacco use, tobacco cessation, and tobacco control public policy. Trained as a general internist, she is Associate Chief of the Division of General Internal Medicine at Massachusetts General Hospital, a Professor of Medicine at Harvard Medical School, and Past President of both the Society for Research in Nicotine and Tobacco and the Society of General Internal Medicine. Dr. Rigotti founded and directs the Tobacco Research and Treatment Center at Massachusetts General Hospital. It combines a clinical service (MGH Tobacco Treatment Smoking Service) with a multidisciplinary research group whose mission is to develop innovative and effective smoking cessation treatment and tobacco control policy approaches. Her research includes evaluations of tobacco control public policies and clinical trials of behavioral and pharmacologic smoking cessation treatments, with a focus on identifying system-level interventions suitable for various inpatient and outpatient health care settings in the U.S. and globally. She co-led the American College of Cardiology’s 2018 Consensus Decision Pathway on Tobacco Cessation Treatment. Dr. Rigotti was a member of the committee that produced the 2018 U.S. National Academies of Science, Engineering, and Medicine’s  Report on the Public Health Consequences of Electronic Cigarettes.  Her current work addressing the role of e-cigarettes for tobacco smoking cessation and harm reduction.  Dr. Rigotti has authored over 300 publications.

If you cannot see the full list of speakers required for this page please make sure you have ordered all speakers in your custom list.
Edit Custom Order Here »
Only administrators can see this message